Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.
‘PrEP for Women Too’ Campaign Aims to Bring This Empowering HIV Prevention Tool to More Black and Latinx Women
Despite PrEP being safe to take for people of all genders, there’s still a lag in uptake among cisgender women.
HIV infection rates among Black women in the U.S. have fallen sharply over the past decade, but look closer and the numbers still paint a troubling story.
Oct. 15, 2020: Adherence barriers among Latinx MSM; Atlanta's Ending the HIV Epidemic priorities; Ryan White HIV service coordination; PrEP, white coat dosing, and drug resistance.
Oct. 1, 2020: HIV surveillance trends among U.S. MSM; health insurance and viral suppression; PrEP prescribing among motivated clinicians; PrEP sharing between MSM.
Sept. 10, 2020: Concomitant use of vaginal rings with condoms; benefits of more frequent HIV screening for young MSM; Black MSM, substance use, and the PrEP continuum; HIV outcomes stratified by anti-LGTBQ policy across U.S. states.
July 30, 2020: HIV prevention shortfalls among adolescents of color; PrEP use among trans people; PrEP information gaps among women of color; the case for vacation-based (a.k.a. episodic) PrEP.
July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.
New data presented at AIDS 2020 show the long-acting injectable drug cabotegravir proved superior to daily oral TDF/FTC for MSM and transgender women.
June 18, 2020: Existing evidence-based interventions aren't enough to close HIV's racial gap; transgender patient outcomes in the HIV care continuum; meeting long-term needs of formerly incarcerated people; acute respiratory illness severity and HIV status.